non-small cell lung cancer

Fierce Pharma

Akeso, Summit's ivonescimab ups PD-1 in chemo combo in 1L NSCLC

HARMONi-6 marks the first phase 3 trial in which a regimen has beaten the combination of a PD-1 inhibitor and chemotherapy on PFS in first-line NSCLC.

Angus Liuu Oct 19, 2025 10:45am

Cancer mutation precision medicine oncology targeted

ESMO: Tubulis' next-gen ADC lives up to hype with 59% ORR

Oct 19, 2025 4:15am

Fierce Pharma

Summit's global PD-1xVEGF data show new promising OS trend

Sep 7, 2025 3:30am

Fierce Pharma

Akeso, Summit's PD-1xVEGF drug meets OS goal for the first time

Aug 26, 2025 11:36am

Prelude calls it curtains on lead SMARCA2 cancer asset

Aug 14, 2025 10:44am

graphic image of China flags overlapping with US flags

Instil's licensed PD-L1xVEGF bispecific shows promise in China

Jul 31, 2025 2:10pm